Literature DB >> 7890214

Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole.

R P Logan1, M M Walker, J J Misiewicz, P A Gummett, Q N Karim, J H Baron.   

Abstract

Omeprazole is a powerful inhibitor of gastric acid and may suppress Helicobacter pylori by effecting the pKa of H pylori urease, by altering the pattern of infection, or by promoting overgrowth of other bacteria. At routine endoscopy H pylori was detected by histology and culture before and after four weeks' treatment with omeprazole, 40 mg each morning. A 13C-urea breath test was also done at t = 0, 2, 4, and 6 weeks. Thirty nine patients with duodenal ulcer (n = 25) or reflux oesophagitis (n = 14) were studied, of whom 29 of 39 had H pylori infection. During omeprazole treatment, 13C-urea breath test values fell significantly--mean (SEM) values before treatment and at four weeks were 23.0 (2.1) and 15.5 (2.7) per mil respectively, p < 0.001. Before treatment H pylori was seen in 28 of 29 antral, 29 of 29 corpus, and 28 of 29 fundic biopsy specimens. After four weeks of omeprazole treatment, the histological density of H pylori in the antrum and corpus was reduced (p < 0.001), while that in the fundus was increased. The migration of H pylori from the antrum to the fundus was associated with a corresponding decrease in the activity of antral gastritis. H pylori was not seen in antral biopsy specimens from 12 of 29 patients whose median excess delta 13CO2 excretion fell from 23.0 to 9.9 per mil. In the body mucosa, 26 of 29 specimens were still positive for H pylori and there was no significant change in the gastritis type. Two weeks after finishing treatment, the mean (SEM) excess delta 13CO2 excretion returned to levels before treatment. Omeprazole decreases antral H pylori colonisation but increases that in the fundus. The changes in the intragastric distribution of the organism are associated with concomitant changes in the activity of gastritis and are matched by a progressive fall in the excretion of delta 13CO2.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7890214      PMCID: PMC1382345          DOI: 10.1136/gut.36.1.12

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  Lansoprazole, a novel benzimidazole proton pump inhibitor, and its related compounds have selective activity against Helicobacter pylori.

Authors:  T Iwahi; H Satoh; M Nakao; T Iwasaki; T Yamazaki; K Kubo; T Tamura; A Imada
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

2.  Duodenal ulcer: the villain unmasked?

Authors:  A R Axon
Journal:  BMJ       Date:  1991-04-20

3.  Omeprazole therapy modifies the gastric localization of Helicobacter pylori.

Authors:  S Vigneri; R Termini; A Scialabba; G Pisciotta; F Di Mario
Journal:  Am J Gastroenterol       Date:  1991-09       Impact factor: 10.864

4.  Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors:  E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

5.  Potent inhibitory action of the gastric proton pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells.

Authors:  K Nagata; H Satoh; T Iwahi; T Shimoyama; T Tamura
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

6.  Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication.

Authors:  J Weil; G D Bell; K Powell; A Morden; G Harrison; P W Gant; P H Jones; J E Trowell
Journal:  Aliment Pharmacol Ther       Date:  1991-06       Impact factor: 8.171

7.  Development of a 14C-urea breath test in ferrets colonised with Helicobacter mustelae: effects of treatment with bismuth, antibiotics, and urease inhibitors.

Authors:  A A McColm; J A Bagshaw; C F O'Malley
Journal:  Gut       Date:  1993-02       Impact factor: 23.059

8.  Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial.

Authors:  D Y Graham; G M Lew; D G Evans; D J Evans; P D Klein
Journal:  Ann Intern Med       Date:  1991-08-15       Impact factor: 25.391

9.  The correlation between acid suppression and peptic ulcer healing.

Authors:  R H Hunt; C W Howden; D B Jones; D W Burget; G D Kerr
Journal:  Scand J Gastroenterol Suppl       Date:  1986

10.  Effect of omeprazole on H. pylori after two weeks of treatment.

Authors:  A Archimandritis; M Tjivras; P Davaris; A Fertakis
Journal:  Ital J Gastroenterol       Date:  1991 Jul-Aug
View more
  69 in total

1.  Gastroesophageal reflux and Helicobacter pylori: a review.

Authors:  F Pace; G Bianchi Porro
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

2.  Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer.

Authors:  J Labenz; B Tillenburg; U Peitz; E Verdú; M Stolte; G Börsch; A L Blum
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

3.  Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.

Authors:  A B R Thomson; M Keelan; R Lastiwka; S Appelman-Eszczuk; L Zuk; L Drozdowski; A Prentice; P Sinclair
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

4.  Upper gastrointestinal endoscopy in Malawi: an opportunity.

Authors:  Will Howson
Journal:  Malawi Med J       Date:  2010-12       Impact factor: 0.875

5.  Diagnostic methods for H. pylori infection: Choices, opportunities and pitfalls.

Authors:  Peter Malfertheiner
Journal:  United European Gastroenterol J       Date:  2015-10       Impact factor: 4.623

Review 6.  Host factors are important in determining clinical outcomes of Helicobacter pylori infection.

Authors:  Tsutomu Chiba; Hiroshi Seno; Hiroyuki Marusawa; Yoshio Wakatsuki; Kazuichi Okazaki
Journal:  J Gastroenterol       Date:  2006-01       Impact factor: 7.527

7.  Real-world Helicobacter pylori diagnosis in patients referred for esophagoduodenoscopy: The gap between guidelines and clinical practice.

Authors:  Dor Shirin; Shay Matalon; Benjamin Avidan; Efrat Broide; Haim Shirin
Journal:  United European Gastroenterol J       Date:  2016-01-08       Impact factor: 4.623

8.  Comparison of Helicobacter pylori infection and gastric mucosal histological features of gastric ulcer patients with chronic gastritis patients.

Authors:  Chuan Zhang; Nobutaka Yamada; Yun-Lin Wu; Min Wen; Takeshi Matsuhisa; Norio Matsukura
Journal:  World J Gastroenterol       Date:  2005-02-21       Impact factor: 5.742

9.  Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial.

Authors:  E J Kuipers; G F Nelis; E C Klinkenberg-Knol; P Snel; D Goldfain; J J Kolkman; H P M Festen; J Dent; P Zeitoun; N Havu; M Lamm; A Walan
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

10.  Tropism for Spasmolytic Polypeptide-Expressing Metaplasia Allows Helicobacter pylori to Expand Its Intragastric Niche.

Authors:  José B Sáenz; Nancy Vargas; Jason C Mills
Journal:  Gastroenterology       Date:  2018-10-01       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.